BioSpace News Archive

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Telix Pharmaceuticals Limited announces that it has completed the submission of a Biologics License Application to the United States Food and Drug Administration for its investigational radiodiagnostic PET1 agent, TLX250-CDx, for the characterisation of renal masses as clear cell renal cell carcinoma.

HUTCHMED Limited announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were published in Nature Medicine.

CatalYm announced positive new follow-up results from its ongoing “GDFATHER” Phase 1/2a trial in an oral presentation at the American Society of Clinical Oncology Annual Meeting 2024 in Chicago.

Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations, after chemoradiotherapy compared to placebo after CRT.

Keymed Biosciences Inc. announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis has been released by way of oral presentation at the European Academy of Allergy and Clinical Immunology Congress 2024.

Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor, in patients with non-small-cell lung cancer in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

Dizal presented the latest data from the inaugural global pivotal study WU-KONG1 Part B of sunvozertinib in relapsed or refractory non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations at the 2024 American Society of Clinical Oncology Annual Meeting.

Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard of care chemotherapy in patients with HR positive, HER2 low metastatic breast cancer and the overall trial population following one or more lines of endocrine therapy.

Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria.